Lipitor, Bextra counterfeiting sentence
Executive Summary
Former NuCare Pharmaceuticals CEO Christopher Lamoreaux sentenced to 21 months in federal prison and ordered to pay $115,278.54 to the company for two counts of mail fraud involving counterfeit versions of Pfizer's Lipitor and Bextra, FDA says Nov. 9. Lamoreaux was found guilty of accepting kickbacks for negotiating a contract for NuCare to purchase and repackage counterfeit and diverted drugs from Albers Medical. He was convicted in Kansas City, Mo. federal court in July following an investigation by FDA's Office of Criminal Investigation...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.